CRESCENT BIOPHARMA, INC. (CBIO) Stock Profile — Insider Trades & Financials

Net Income-$92.4M

Market Cap$504.8M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Joshua Brumm

CEO & Executive Director

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.

Founded: 2003
Employees: 44
Headquarters: Waltham, Massachusetts, United States

⚡

Core Efficiency

ROE?

-45.51%

ROA?

-38.45%

D/E Ratio?

0.18

📊

Profitability Ratios

Current Ratio?

6.56

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Jul 22, 2026 (in 104 days)

Annual Report (10-K) — Based on filing pattern

Jul 22, 2026

Predicted10-K

Feb 26, 2026

10-KQ4 20253d after period end

Nov 6, 2025

10-QQ3 20253d after period end

Jul 31, 2025

10-QQ2 20256d after period end

May 14, 2025

10-QQ1 20252d after period end

Feb 13, 2025

10-KQ4 20246d after period end

Nov 13, 2024

10-QQ3 20240d after period end

Aug 8, 2024

10-QQ2 20241d after period end

May 9, 2024

10-QQ1 20242d after period end

Loading company sections...

CRESCENT BIOPHARMA, INC.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness